The optimal ethanol lock therapy regimen for treatment of biofilm-associated catheter infections: an in-vitro study

Abstract

Ethanol-based lock therapy (LT) solutions are used as an alternative to antibiotics for the conservative management of catheter-related bloodstream infection. However, no clear consensus on regimen or dose has been reached. To find the ethanol-based lock solution containing a sufficiently low concentration of ethanol for reduction of the metabolic activity of bacterial and fungal biofilms. Using an in-vitro model, three concentrations of ethanol (25%, 40%, 70%) were tested, with and without 60 IU of heparin, at six different time-points and against 24h preformed biofilms of Staphylococcus aureus ATCC29213, Staphylococcus epidermidis (clinical isolate), Enterococcus faecalis ATCC33186, Candida albicans ATCC14058, and Escherichia coli ATCC25922. The reduction in the metabolic activity of the biofilm was measured using the tetrazolium salt assay and LT was considered to be successful when metabolic activity fell by >90%. Regrowth inhibition was then tested within 24h and seven days after each LT regimen only at the ethanol concentration of the most successful LT regimen. The most successful LT was achieved with 40% ethanol+60 IU of heparin only at 24, 72, and 24h for seven-day regimens (P<0.05). However, none of the regimens reached 45% RI within seven days of therapy. According to our in-vitro data, an ethanol-based lock solution with 40% ethanol+60 IU heparin administered daily for 72h is sufficient to almost eradicate the metabolic activity of bacterial and fungal biofilms. Future studies are needed to study cell regrowth after LT.